Bliss GVS Pharma Limited (NSE:BLISSGVS)
India
· Delayed Price · Currency is INR 116.42
-2.19 (-1.85%)
Mar 12, 2025, 3:29 PM IST
Bliss GVS Pharma Revenue
Bliss GVS Pharma had revenue of 2.10B INR in the quarter ending December 31, 2024, with 4.83% growth. This brings the company's revenue in the last twelve months to 8.10B, up 7.00% year-over-year. In the fiscal year ending March 31, 2024, Bliss GVS Pharma had annual revenue of 7.70B with 2.48% growth.
Revenue (ttm)
8.10B
Revenue Growth
+7.00%
P/S Ratio
n/a
Revenue / Employee
9.75M
Employees
831
Market Cap
12.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 7.70B | 186.57M | 2.48% |
| Mar 31, 2023 | 7.52B | 41.33M | 0.55% |
| Mar 31, 2022 | 7.47B | 1.70B | 29.50% |
| Mar 31, 2021 | 5.77B | -1.12B | -16.26% |
| Mar 31, 2020 | 6.89B | -2.09B | -23.29% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Zydus Lifesciences | 222.47B |
| Apollo Hospitals Enterprise | 211.46B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Bliss GVS Pharma News
- 3 months ago - Bliss GVS Pharma shares surge 4% after company receives GMP Compliance certification for its manufacturing facilities in Palghar - Business Upturn
- 3 months ago - Bliss GVS Pharma receives GMP Compliance certification for manufacturing facilities in Palghar, Maharashtra - Business Upturn